01.医生概述

医生概述

Suresh S. Ramalingam博士is a thoracic oncologist and deputy director at Winship Cancer Institute of Emory University in美国佐治亚州亚特兰大。他获得了内科和医学肿瘤学的董事会认证。在加入Winship Cancer Institute之前，Ramalingam博士在韦恩州立大学完成了内科住院医师，并在血液学和医学肿瘤学方面完成了研究金匹兹堡大学癌症研究所。

Dr. Ramalingam serves as an investigator and physician, specializing in small cell and non-small cell lung cancer. He has authored more than 200 publications, and also serves as a section editor for “Chest Diseases” in Cancer. In his clinical trial research, Dr. Ramalingam explores the development of immune checkpoint inhibitors for small cell and non-small cell lung cancer. He also researchesimmunotherapyand potential outcomes for patients with an EGFR mutation, which causes lung cancer.

02.快速事实

医生快速事实

Main Specialty:胸肿瘤学

Other Interests & Specialties:Hematology, immunotherapy, non-small cell lung cancer, small cell lung cancer and targeted therapy.

认证，奖励和荣誉：Georgia Cancer Coalition Distinguished Cancer Scholar, President of the Georgia Society of Oncology, James Eckman Award for Excellence in Teaching at Emory, ECOG-ACRIN Young Investigator Award, NCI Cancer Clinical Investigator Team Leadership Award, Atlanta’s Top Doctors by Atlanta Magazine in 2018, member of MilliPub Club at Emory University School of Medicine

Education & Experience:

• 印度马德拉斯大学马德拉斯大学的基尔普克医学院的医学学位
• 韦恩州立大学的内科居住
• 匹兹堡大学癌症研究所血液学和医学肿瘤学奖学金

03.出版物

出版物

Nivolumab加上晚期非小细胞肺癌中的ipilimumab。新英格兰医学杂志。2019年11月； 381（21）：2020-2031。doi：10.1056/NEJMoa1910231

Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma。胸肿瘤学杂志。2009年1月； 4（1）：97-101。doi：10.1097/jto.0b013e318191520c

Recent advances in the treatment of malignant pleural mesothelioma。胸肿瘤学杂志。2008年9月； 3（9）：1056-64。doi：10.1097/jto.0b013e3181834f66